The home grown sleeper that became a $2 billion a year global giant

 RESMED

By TIM BOREHAM

ASX: RMD (Chess depository interests); New York Stock Exchange: RMD

Share price: $12.48; Market cap: $17.82 billion

Shares on issue: 142,891,971 US shares; 1,428,919,708 CDIs*

Financials (December half): revenue $US1,125 billion ($A1,409 billion) (up 13%), operating income $US258.5 million (up 35%), net income $US95,651,000 ($A119,792,200) (down 37%).

Read more...

From disposable nappies to stem cells: how Cynata got out of the poo

Posted on Feb 10 2018

 CYNATA THERAPEUTICS

ASX CODE: CYP

SHARE PRICE: 81c

SHARES ON ISSUE: 90.06m

MARKET CAP: $73m

CEO: Dr Ross Macdonald

BOARD: Dr Paul Wotton (chairman), Ross Macdonald, Dr Stewart Washer, Dr John Chiplin, Peter Webse

 FINANCIALS (December quarter) revenue nil, cash generated $145,000, cash balance $8.839mm*, estimated December quarter cash burn $1.753m

Read more...

Cracking the cure for acne: a bright ‘spot’ in a terrible market?

Posted Feb 6 2018

Dr Boreham’s Crucible

MGC Pharmaceuticals (MXC) 11.5c

BOD Australia (BDA) 56c

Botanix (BOT) 14c (trading halt)

Zelda Therapeutics (ZLD) 12.5c

Creso Pharma (CPH) 92c

For a website with articles such as how to grow the best organic weed and where to buy the best ‘dab rigs’*, hightimes.com should be a one-eyed advocate of the virtues of cannabis.

Read more...